pills-384846_960_720-150x150-5307011Governor Cuomo says that controlling the cost of prescription drugs will be part of his agenda in 2020. Four bills currently awaiting his signature or veto give him a chance to get started in 2019.

The medication-related bills were passed by the Legislature earlier this year and recently delivered to his office for final action. Each would intervene in the complex drug market in a different way, but all, if signed, are likely to result in higher overall costs for consumers, employers and taxpayers – adding to what are already the highest premiums in the lower 48 states.

The most sweeping of the three measures, A. 2836/S. 6531, seeks to regulate pharmacy benefit managers (PBMs), the companies that negotiate prices with drug manufacturers on behalf of health plans and employers.

Because the price-setting process is so murky, and because PBMs generate substantial revenues without ever physically handling a product, they are widely distrusted by other players in the health-care system and state lawmakers of both parties.

The regulation bill, cosponsored by Assembly Health Chairman Richard Gottfried and Senate Insurance Chairman Neil Breslin, easily passed in both chambers with bipartisan support – 147-0 in the Assembly and 49-13 in the Senate.

However, the final language came together quickly in the final days of the legislative session, and includes several problematic provisions.

One requires PBMs to act “for the best interests primarily of the covered individual, and the health plan and the provider” – which would be difficult, since the interests of those three groups often conflict. Another clause creates the right to sue PBMs “for any injury or loss … caused by any violation of such duties, obligations or requirements,” which is bound to unleash a lot of costly litigation.

As written, the bill would also subject the companies to overlapping regulation by two state agencies, the departments of Health and Financial Services, which is likely to create redundancy and conflict.

For these and other reasons, the legislation would impede PBMs from fulfilling their core function of negotiating price discounts, which could leave consumers worse off in the end.

A second bill awaiting Cuomo’s final action, A. 2969/S. 2849, would bar insurers from changing their drug formularies (which are often managed by PBMs) in the middle of a plan year. This is meant to protect patients from unexpected coverage changes that could force them to switch medications or pay higher out-of-pocket charges. 

Health plans and employers have objected that this rule would hamstring their ability to manage drug costs – since manufacturers could hike prices early in the year but not lose their formulary slots until months later.

Tellingly, labor unions raised this same objection – and the legislation was promptly amended to exempt collectively bargained plans from its requirements.

The two final bills, A. 2785/S. 3118 and A. 3009/S. 4078, would mandate coverage of drug “synchronization,” in which pharmacies provide partial refills for some medications so that a patient can refill all of his or her prescriptions at once. One bill imposes this requirement on Medicaid, and the other governs private insurance.

The New York Health Plan Association opposes these bills on grounds that they require insurers to pay pharmacists the same fee for partial refills as they do for 30-day refills, which would be likely to increase costs for plans and premium payers.

Earlier this week, Cuomo said his 2020 agenda would include a three-point plan for lowering drug costs: imposing a $100 monthly cap on out-of-pocket insulin costs for insured patients, empowering the Department of Financial Services to investigate price spikes by drug manufacturers, and creating a commission to explore the importation of lower-cost pharmaceuticals from Canada.

The details of those proposals remain to be seen.

Meanwhile, the governor faces a deadline to sign or veto the two drug synchronization bills by Saturday, and the PBM regulation and formulary bills by Dec. 28. Those decisions will be an early signal of how serious he is about truly controlling drug costs.

 

About the Author

Bill Hammond

As the Empire Center’s senior fellow for health policy, Bill Hammond tracks fast-moving developments in New York’s massive health care industry, with a focus on how decisions made in Albany and Washington affect the well-being of patients, providers, taxpayers and the state’s economy.

Read more by Bill Hammond

You may also like

The House GOP’s Shrinking Budget Plan Could Still Cost New York Billions

The likely impact of federal health-care cutbacks has diminished in recent days as House Republican leaders backed away from some of their bigger-ticket proposals, reducing the estimated savings to $625 billion from previous figures of $715 billion and $8 Read More

How Medicaid ‘Expansion’ Changes Could Affect New York

As House Republicans consider cutbacks to federal Medicaid funding, their focus has turned to the so-called expansion population. Although the details of remain undetermined, the s Read More

New York’s Home Health Workforce Jumps by Another 10 Percent

New York's home health employment is continuing to soar, growing by 57,000 jobs or 10 percent from 2023 to 2024, according to newly released data from the U.S. Bureau of Labor Statistics. Read More

Immigrant Enrollment in ‘Emergency Medicaid’ Surges to 480,000

One of the biggest drivers of New York's Medicaid enrollment growth over the past decade has been "emergency Medicaid" for undocumented immigrants, newly released state records show. Read More

Upstate Insurance Customers Pay the Price for Medicare’s Hospital Rate Hike

A billion-dollar Medicare windfall for upstate hospitals has turned into a crisis for upstate health insurers that's threatening to disrupt coverage for millions of New Yorkers. The Read More

New York’s Proposed ‘MCO Tax’ Would Generate a Fraction of What Lawmakers Expected

The Hochul administration's proposed "MCO tax" would generate far less than the $4 billion in extra federal aid anticipated by state lawmakers when they approved the concept this spring, according to documents obtained by t Read More

Cuomo’s House Testimony Added New Misinformation about Covid in Nursing Homes

Throughout the scandal over former Governor Andrew Cuomo's handling of Covid-19 in nursing homes, Cuomo and his administration repeatedly spread bad information – misstating how its policies had worked, understating death Read More

Hochul Hides the Specifics of a Looming Tax on Health Insurance

The Hochul administration has requested federal approval for a multibillion-dollar "MCO tax" on health plans without announcing the move or providing details to the public. As by l Read More